Changes in dual energy X-ray absorptiometry parameters in postmenopausal women with osteoporosis who received at least 12 months of denosumab treatment
Effectiveness of denosumab treatment in postmenopausal osteoporosis
Keywords:Osteoporosis, Denosumab, Dual energy X-ray absorptiometry
Background/Aim: Denosumab is a human monoclonal antibody that binds to the receptor-activated nuclear factor kappa beta ligand (RANKL). Densosumab leads to a reduction in bone resorption by inhibiting RANKL and has been approved for treating postmenopausal osteoporosis (OP). The present study investigated real life data by evaluating the demographic data of postmenopausal patients with OP who received denosumab treatment and the changes in dual energy x-ray absorptiometry (DEXA) parameters before and after denosumab treatment.
Methods: This retrospective cohort study included 49 postmenopausal female patients followed in our OP outpatient clinic who were treated with 60 mg subcutaneous denosumab every six months for at least 12 months. The study retrospectively analyzed and recorded patient age, body mass index, age of menopause, fracture history, antiresorptive and/or anabolic drug treatment history, and pre- and post-denosumab T-scores in addition to L1–4, femoral neck, and total hip bone mineral densities (BMDs) on DEXA scans. The changes that occurred before and after the treatment in addition to those that occurred after the treatment based on whether previous anabolic or antiresorptive agents had been used were statistically compared.
Results: The L1–4 and total hip T-scores and L1–4 and total hip BMD values measured prior to denosumab treatment showed a statistically significant increase after denosumab treatment (P < 0.001, P = 0.002, P = 0.028, and P = 0.002, respectively). No statistically significant changes in the femoral neck T-score and BMD after denosumab treatment compared to that before denosumab use (P = 0.056 and P = 0.138, respectively) were found. Furthermore, no statistically significant difference between the pre- and post-denosumab DEXA parameters in the patients who used antiresorptive agents and those who did not (P > 0.05) was found. Additionally, pre- and post-denosumab parameters were not statistically significantly different between those who received and did not receive anabolic therapy before denosumab (P > 0.05).
Conclusion: Denosumab treatment for postmenopausal OP leads to a significant increase in lumbar and total hip T-scores and BMDs.
Armas LA, Recker RR. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinology and Metabolism Clinics of North America. Endocrinology and Metabolism Clinics. 2012 Sep 1;41(3):475-86. DOI: https://doi.org/10.1016/j.ecl.2012.04.006
Kuru P, Akyüz G, Cerşit HP, Çelenlioğlu AE, Cumhur A, Biricik S, et al. Fracture history in osteoporosis: risk factors and its effect on quality of life. Balkan Medical Journal. 2014 Dec;31(4):295-301. DOI: https://doi.org/10.5152/balkanmedj.2014.13265
Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporosis International. 2012 Mar 1;23(3):949-55. DOI: https://doi.org/10.1007/s00198-011-1655-5
Aziziyeh R, Perlaza JG, Saleem N, Kirazlı Y, Akalın E, McTavish RK, et al. The burden of osteoporosis in Turkey: a scorecard and economic model. Archives of Osteoporosis. 2020 Dec;15(1):128. DOI: https://doi.org/10.1007/s11657-020-00801-9
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019 Jan 18;30(1):3-44. DOI: https://doi.org/10.1007/s00198-018-4704-5
Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine. 2009 Aug 20;361(8):756-65. DOI: https://doi.org/10.1056/NEJMoa0809493
McClung MR. Denosumab for the treatment of osteoporosis. Osteoporosis and Sarcopenia. 2017 Mar 1;3(1):8-17. DOI: https://doi.org/10.1016/j.afos.2017.01.002
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The Lancet Diabetes and Endocrinology. 2017 Jul 1;5(7):513-23. DOI: https://doi.org/10.1016/S2213-8587(17)30138-9
Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. The Journal of Clinical Endocrinology and Metabolism. 2020 Mar;105(3):587-94. DOI: https://doi.org/10.1210/clinem/dgaa048
Hadji P, Papaioannou N, Gielen E, Tepie MF, Zhang E, Frieling I, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporosis International. 2015 Oct 1;26(10):2479-89. DOI: https://doi.org/10.1007/s00198-015-3164-4
Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporosis International. 2015 Jan 1;26(1):361-72. DOI: https://doi.org/10.1007/s00198-014-2871-6
Cairoli E, Palmieri S, Goggi G, Roggero L, Arosio M, Chiodini I, et al. Denosumab or oral bisphosphonates in primary osteoporosis: a ‘real-life’ study. Journal of Endocrinological Investigation. 2018 Aug 1;41(8):1005-13. DOI: https://doi.org/10.1007/s40618-018-0829-9
Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis International. 2015 Dec 1;26(12):2773-83. DOI: https://doi.org/10.1007/s00198-015-3234-7
Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JE, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. Journal of Bone and Mineral Research. 2014 Sep;29(9):2051-6. DOI: https://doi.org/10.1002/jbmr.2236
Ferrari S, Libanati C, Lin CJ, Brown JP, Cosman F, Czerwiński E, et al. Relationship between bone mineral density T‐score and nonvertebral fracture risk over 10 years of denosumab treatment. Journal of Bone and Mineral Research. 2019 Jun;34(6):1033-40. DOI: https://doi.org/10.1002/jbmr.3722
Adami S, Libanati C, Boonen S, Cummings SR, Ho PR, Wang A, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM Trial. Journal of Bone and Joint Surgery. 2012 Dec 5;94(23):2113-9. DOI: https://doi.org/10.2106/JBJS.K.00774
McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporosis International. 2017 May 1;28(5):1723-32. DOI: https://doi.org/10.1007/s00198-017-3919-1
Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. The Journal of Clinical Endocrinology and Metabolism. 2011 Apr 1;96(4):972-80. DOI: https://doi.org/10.1210/jc.2010-1502
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017 Dec 1;105:11-7. DOI: https://doi.org/10.1016/j.bone.2017.08.003
Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Therapeutic Advances in Musculoskeletal Disease. 2018 Nov;10(11):209-23. DOI: https://doi.org/10.1177/1759720X18805759
Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. Journal of Bone and Mineral Research. 2012 Jul;27(7):1471-9. DOI: https://doi.org/10.1002/jbmr.1613
Jamal SA, Ljunggren O, Stehman‐Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone and Mineral Research. 2011 Aug;26(8):1829-35. DOI: https://doi.org/10.1002/jbmr.403
Fraser TR, Flogaitis I, Moore AE, Hampson G. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: A 'real-life' study. Journal of Endocrinological Investigation. 2020 Apr;43(4):469-75. DOI: https://doi.org/10.1007/s40618-019-01131-5
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomized controlled trial. Lancet. 2015 Sep 19;386(9999):1147-55. DOI: https://doi.org/10.1016/S0140-6736(15)61120-5
- 183 207
How to Cite
Copyright (c) 2022 Meryem Yilmaz Kaysin, İlknur Aktaş, Feyza Ünlü Özkan, İrem Buse Kurucu Zeytin
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.